## INDEX

<table>
<thead>
<tr>
<th>A</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>abacavir</td>
<td>379, 385</td>
<td></td>
</tr>
<tr>
<td>absolute risk (versus relative risk)</td>
<td>298</td>
<td></td>
</tr>
<tr>
<td>absorption, pharmacokinetics</td>
<td>98, 113</td>
<td></td>
</tr>
<tr>
<td>academia, interactive role in drug safety</td>
<td>391</td>
<td></td>
</tr>
<tr>
<td>acarbose</td>
<td>302</td>
<td></td>
</tr>
<tr>
<td>acceptor group, metabolism</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>acetylation</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>acetylcholine</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>acquired QT prolongation</td>
<td>81-86</td>
<td></td>
</tr>
<tr>
<td>acquired QT shortening</td>
<td>184-186</td>
<td></td>
</tr>
<tr>
<td>action potential phases</td>
<td>65</td>
<td></td>
</tr>
<tr>
<td>depolarization</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>repolarization</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>resting</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>active postmarketing surveillance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>See postmarketing surveillance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>adenine</td>
<td>27-29</td>
<td></td>
</tr>
<tr>
<td>adherence</td>
<td>330, 346-348</td>
<td></td>
</tr>
<tr>
<td>adjudication, of cardiovascular events</td>
<td>310, 322</td>
<td></td>
</tr>
<tr>
<td>administrative claims databases</td>
<td>277</td>
<td></td>
</tr>
<tr>
<td>ADOPT (A Diabetes Outcome Progression Trial)</td>
<td>307</td>
<td></td>
</tr>
<tr>
<td>adrenal glands</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>adrenaline</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>adverse drug reactions</td>
<td>232, 263</td>
<td></td>
</tr>
<tr>
<td>type A (dose-related)</td>
<td>264</td>
<td></td>
</tr>
<tr>
<td>type B (bizarre)</td>
<td>265</td>
<td></td>
</tr>
<tr>
<td>adverse events</td>
<td>203-222</td>
<td></td>
</tr>
<tr>
<td>Adverse Event Reporting System</td>
<td>260</td>
<td></td>
</tr>
<tr>
<td>Acorpyrum pernix sodium ion channel</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>age, risk factor for torsades de pointes</td>
<td>358</td>
<td></td>
</tr>
<tr>
<td>Agency for Healthcare Research and Quality</td>
<td>334</td>
<td></td>
</tr>
<tr>
<td>AIDS</td>
<td>235</td>
<td></td>
</tr>
<tr>
<td>all-or-none phenomenon, statistical significance</td>
<td>313</td>
<td></td>
</tr>
<tr>
<td>alleles</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>alpha-subunit, ion channel</td>
<td>46, 69-70</td>
<td></td>
</tr>
<tr>
<td>alternative hypothesis, statistical</td>
<td>170</td>
<td></td>
</tr>
<tr>
<td>alternative splicing</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>ambulatory care settings, medication errors</td>
<td>330</td>
<td></td>
</tr>
<tr>
<td>amino acids</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>analysis of covariance</td>
<td>166</td>
<td></td>
</tr>
<tr>
<td>anaphylaxis</td>
<td>127</td>
<td></td>
</tr>
<tr>
<td>angina</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>anthracyclines</td>
<td>317</td>
<td></td>
</tr>
<tr>
<td>antidiabetic drugs</td>
<td>302</td>
<td></td>
</tr>
<tr>
<td>antihistamines, effects on QT interval</td>
<td>286, 288</td>
<td></td>
</tr>
<tr>
<td>antihyperglycemic agents</td>
<td>302</td>
<td></td>
</tr>
<tr>
<td>antiserum</td>
<td>127</td>
<td></td>
</tr>
<tr>
<td>aorta</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>aortic valve</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>APPROVe (Adenomatous Polyp Prevention on Vioxx) trial</td>
<td>296</td>
<td></td>
</tr>
<tr>
<td>aprotinin</td>
<td>315</td>
<td></td>
</tr>
<tr>
<td>area under the curve</td>
<td>113</td>
<td></td>
</tr>
<tr>
<td>arrhythmias, cardiac</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>arsenic trioxide</td>
<td>86, 291</td>
<td></td>
</tr>
<tr>
<td>arthritis</td>
<td>294</td>
<td></td>
</tr>
<tr>
<td>aspirin</td>
<td>295</td>
<td></td>
</tr>
<tr>
<td>assay sensitivity</td>
<td>152</td>
<td></td>
</tr>
<tr>
<td>astemizole</td>
<td>286</td>
<td></td>
</tr>
<tr>
<td>asthma</td>
<td>341</td>
<td></td>
</tr>
<tr>
<td>atherosclerosis</td>
<td>88, 193</td>
<td></td>
</tr>
</tbody>
</table>
atherosclerotic disease 91
atrial 55
atrial arrhythmias 74
chronic atrial fibrillation 386
atrial peak mitral inflow velocity 318
atrioventricular node 64
automaticity 64
autonomic nervous system 60-61
auxiliary subunits, ion channels.
See beta-subunit.
aviation industry, safety systems in 21, 332, 346

B
backbone, of drug molecule 28, 51, 96
bases, DNA 29
Bazett's correction formula (QTcB) 121-122, 142
beagle dog 121
behavioral cardiac safety,
definition 20
BcKm-I 129
benefit-risk analysis, importance of 380
balance or profile 13, 137
estimation of 13-15
favorable 13
lifecycle assessment 378
role in clinical practice 15, 390
role in regulatory decision making 14, 388-390
beta-subunit, ion channel 79
binding, drug to receptor 97
bioassay, TQT study as 150
bioavailability 98
bioinformatics 99-100
biological plausibility 53, 260
biological relevance 25, 195
biologics, large-molecule drugs 126
Biologicals License
Application 10

biology, central role in clinical research 195
biomarkers 386
pharmacogenomic 385
biopharmaceutical, terminology 126
biopsychosocial perspective 349
biotechnology medicines,
terminology 126
black box warning 330
blood lipid concentrations 320
blood pressure
diastolic. See diastolic blood pressure
high. See hypertension
mean arterial pressure 60
measurement of 59
pulse pressure 59
systolic. See systolic blood pressure
blood samples 198
body weight 320
bond, atomic 27
boxed warnings. See black box warnings
Bradford Hill criteria, for potential
causal links 260
bradycardia 317
brainstem 61

C
C peptide 301
camptosar 385
Canadian Cardiovascular Society 89
carcinogenicity 116
cardiac conduction system 62
cardiac dimensions 320
cardiac electrophysiology 62
cardiac output 58
Cardiac Safety Research Consortium 182, 393
cardiac transmembrane potential 64
cardiomyopathy 317
Cardiovascular and Renal Drugs
Advisory Committee 303
care givers, residential homes 330
carrying over effects, in cross-over study designs 151
cascade of biological information 25
case series 274
case-control studies 275
catalysis 49
catalysts 48
categorical data 166
celecoxib 295
Celera Genomics 33
cells 40
eukaryotic 42
intraacellular membranes 43
membrane 43
cellular control mechanisms 84
Center for Biologies Evaluation and Research 9
Center for Drug Evaluation and Research 9
Center for Patient Safety 335
central tendency 200
centralised procedure 11
cerebral hemorrhage 294
change scores
lab data 200
TQT study 166
channelopathies, cardiac 75-80
chaperones, cytosolic 71, 85
Chinese hamster ovary cells 120
cholesterol 193, 201
chromosomes 30
cisapride 286, 289
molecular weight 126
CLASS (Celecoxib Arthritis Safety Study) 295
clinical laboratory tests 198
clinical pharmacology unit 135
clinical research, simpler definition 196
Clinical Trial Application 10
clinical trial registries. See registries
Cmax 113, 156, 163
coagulation profiles 320
Cochran Q test 313
Cochrane Collaboration 255
cohort studies 275
colorectal polyps 295
Committee for Medicinal Products for Human Use 11
Committee for Proprietary Medicinal Products 289
Committee on Data Standards for Patient Safety 342
Committee on Oversight and Government Reform 303
Committee on Safety of Drugs 285
community care settings, medication errors 30
Comparative Effectiveness Research Act 392
composite endpoints 302
computational drug design ligand-based approach 103
target-based approach 104
computer-assisted molecular design 100
computers, use in bioinformatics 100
concentration-response relationship 99, 362
Concerned Member State 11
concordance 348-350
confidence intervals one-sided, definition 148
two-sided, definition 148
use of 170-175, 252, 312
conformational defects, proteins 84
congestive heart failure. See heart failure
Congress, United States 374, 377, 378
congressional appropriations 375
conservative approach, early drug development 391
continuous variable/outcome 165
core ECG lab 158
core echocardiography lab 318
coronary artery disease. See coronary heart disease
coronary-artery surgery 315
coronary circulation 57
coronary heart disease 88
correcting QT for heart rate. See QTC data
Council for International Organizations of Medical Sciences 269
covariate adjustments 147, 315
COX-2 inhibitors. See selective cyclooxygenase-2 inhibitors
Critical Path Initiative 393
Critical Path Opportunities List 393
Crossing the Quality Chasm, report by the Institute of Medicine 339-342, 380
cross-over design, use in TQT study 151, 181
cross-sectional studies 275
crude rate, of events 221
crystallographic structure, hERG 102
culture of blame 338
culture of safety 338, 343
CYP2D6, importance in drug metabolism 384
cytochrome P450 enzymes 50
cytosol, cell 43
cytosine 27

D
data abstraction and acquisition, in meta-analysis 242
data mining 278
Data Monitoring Safety Board 297
decentralised procedure 11
decision analysis 357, 381-383
delayed afterdepolarization 81
denominator, use in ratios 12
depolarization 67
depolarizing ionic currents 66
descriptive statistics 166
design, drug molecule 93, 95
dessertenne, author 288
developmental biology 36
dexamethasone 294
diabetes mellitus 300, 341
diagnostic tests 386-387
DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) trial 307
diastolic 57
diastolic blood pressure 59
digital ECG warehouse 183
dispersion of repolarization 83
disposition, pharmacokinetics 113
dissociation, drug from binding site 82
Division of Drug Risk Evaluation 271
Division of Medication Errors and Technical Support 271
Division of Surveillance, Research, and Communication Support 271
DNA 26
docking, drug with receptor 96-97
Doppler echocardiography 317
double delta, calculation in TQT study 167
double helix 29
droperidol 286
Drosophila melanogaster 31
drug-induced QT prolongation. See acquired QT prolongation
drug-induced QT shortening. See acquired QT shortening
Drug Safety and Risk Management Advisory Committee 303
drug trapping, in hERG channel 82
drug withdrawals, from market 14, 286-289, 297
dystrophin 34
E

E. Coli 127

eag, Drosophila gene 32, 68
early afterdepolarization 81
early peak mitral inflow velocity 318
echocardiography. See Doppler echocardiography
ecological studies 274
etopic beat 81
effectiveness, drug 3-4, 231
efficacy, drug 3, 231
eletrocardiogram (ECG) 62
12-lead ECGs 155
electrolyte 42
electrolyte abnormalities 358
electronic decision support tools 379
electronic medical/health records 277, 343, 379
electrophysiology studies
in vitro 119
in vivo 120
eligibility criteria
clinical trial 320
meta-analysis 242-244
elimination, pharmacokinetics 114
embryonic kidney cells, human 120
eendocrine system 61
Endocrinologic and Metabolic Drugs Advisory Committee 303
endoplasmic reticulum 71
endpoints, TQT study 158
energetically favorable interaction, drug with receptor 97
engineering, drug molecules 97-99
enzymes 48
metabolic 49
protease 84
epidemiological studies, historical development of 260-261
epinephrine. See adrenaline
equitable health care 341
estimated risk difference 208
EudraVigilance 394
eukaryotic cell. See cell
European Commission 6
European Federation of
pharmaceutical industries and associations 6
European Medicines Agency 10-11
documents and websites 394-395
statements concerning
rosiglitazone 304-305
European Risk Management Strategy 394
European Union 6
EU Scientific Opinion 11
Events Adjudication Committee 308
excess risk 209
exclusivity period, drug 387
exon 34
experimental control 151
experimental study design 261
exposure-response modeling.
See pharmacokinetic/
pharmacodynamic modeling
expression, gene 36
Extensible Markup Language 158

F
Federal Food, Drug and Cosmetic Act 196
female sex, risk factor for torsades de pointes 358
fenfluramine 294
first time in human/man study 4, 135
five rights, of safe medication use 331
fluid retention 293
folding, protein 40, 85
Food and Drug Administration 9
Food and Drug Administration Amendments Act 357, 375
Food and Drug Administration Modernization Act 9, 368
four-arm TQT study design 154
Framingham Q1 correction 143
Fridericia's correction formula (QTcF) 122, 142
functional group, drug molecule 94, 96
fusion proteins 130
molecular weight 126

glycosylation 50, 71
government, interactive role in drug safety 391
grepafloxacin 286
guanine 27

H
half-life 113
hazard ratio 309
Health Canada 136
"Question and Answer" documents, TQT study 290
health care expenditures, effects of medication errors 330
health care practitioners continuing education 368
letters 368
training programs 368
heart 55-58
heart attack, See myocardial infarction
heart attack, See myocardial infarction
heart disease, as chronic condition 341
heartbeat 57
heart failure 88, 90, 176, 293, 308, 317
heart rate 57
heart valves 56
prosthetic 386
hereceptin 385
heredity 36
heritable arrhythmia syndrome, See channelopathies
hERG channel 69
blockade 82, 102
trafficking 71
trafficking deficiency 85-86, 361-362
current 69
gene 69
origin of term 69
heterologous expression systems 119

genes 32-34
evag 32
KCNE1/MiK 79
KCNE2/MiRP1 79
KCNH2/hERG 77
KCNO1 77
SCN5A 77
genetic susceptibility
to (any) adverse drug reaction 54
to torsades de pointes 358
genetics molecular 31
transmission 31
genome 32-35
genomic technology 385
genomics 31
genotoxicity, assessment of 116
genotyping 386
geometry of approach, drug toward receptor 96
gleevec 385
glimepiride 302
glipizide 302
glucose 301
glyburide 302

gain of function, sodium ion channel 77
gastrointestinal bleeding 295
gating properties, of ion channels 47

G

gain of function, sodium ion channel 77
gastrointestinal bleeding 295
gating properties, of ion channels 47
genes 32-34
evag 32
KCNE1/MiK 79
KCNE2/MiRP1 79
KCNH2/hERG 77
KCNO1 77
SCN5A 77
generalized cardiac safety,
definition 19
genetic engineering 126
genetic susceptibility
to (any) adverse drug reaction 54
to torsades de pointes 358
genetics molecular 31
transmission 31
genome 32-35
genomic technology 385
genomics 31
genotoxicity, assessment of 116
genotyping 386
geometry of approach, drug toward receptor 96
gleevec 385
glimepiride 302
glipizide 302
glucose 301
glyburide 302

glycosylation 50, 71
government, interactive role in drug safety 391
grepafloxacin 286
guanine 27

H
half-life 113
hazard ratio 309
Health Canada 136
"Question and Answer" documents, TQT study 290
health care expenditures, effects of medication errors 330
health care practitioners continuing education 368
letters 368
training programs 368
heart 55-58
heart attack, See myocardial infarction
heart disease, as chronic condition 341
heartbeat 57
heart failure 88, 90, 176, 293, 308, 317
heart rate 57
heart valves 56
prosthetic 386
herceptin 385
heredity 36
heritable arrhythmia syndrome, See channelopathies
hERG channel 69
blockade 82, 102
trafficking 71
trafficking deficiency 85-86, 361-362
current 69
gene 69
origin of term 69
heterologous expression systems 119
high-throughput screening 92
hindbrain 61
HLA-B*5701 385
Holter monitoring 155, 157, 317, 360
entire datastream 360
homogeneity, consideration in meta-
analysis 242, 253
homology modeling 104
hormones 61
housekeeping genes and proteins 37
Hsp90 86
human factors research 338
human genome 32-33
human-machine interface 338
human-system interface 338
human pharmacology studies 5, 135-136, 319-320
hybridoma cells 127
hydrochlorothiazide 201
hydroxylation 50
hyper-responder, to drug 26
hypersensitivity reactions 127, 386
hypertension 87, 317
hypoglycemic agents 302
hypokalemia 176
hypotension 317
hypothalamus 61
hysteresis 359

I
$I_{Na}$ 65
$I_{Kr}$ 65, 68
$I_{Ks}$ 65
ibuprofen 295
immortal cells 127
immunoglobulins 127
in silico modeling 2, 101-105
in silico optimization schemes 101
inclusion criteria. See eligibility
criteria, clinical trial
individual corrected QT (QTcI) 143
individual patient/participant
data 245, 310
individual variation
in drug response 25-26
in genomes 34
industry, interactive role in drug
safety 391
inferential statistics 168
inheritance
autosomal dominant 30
autosomal recessive 30
inherited long QT syndrome 75
inherited short QT syndrome 184
inner cavity, hERG channel 82
insulin, endogenous 300
aspart 301
lispro 301
resistance 300
integrated cardiac safety,
definition 17
Integrated Summary of Safety 245
Intent-to-Treat (ITT) analysis
population 314
interactions
drug-drug 264
drug medical device 268
Interdisciplinary Review Team 179
interim analysis 303, 308
International Conference on
Harmonisation 5, 6-8
guidance documents
E3 200
E14 136, 144f, 358
S6 128
S7A 111
S7B 111, 117, 128, 358
International Human Genome
Sequencing Consortium 33
International Society of
Pharmacovigilance 270
intersection-union test 174, 360
intron 34
investigational drug 3, 137
Investigational New Drug Application 10
investigational review board 369-372
iodination 50
ions calcium (Ca²⁺) 66, 361 potassium (K⁺) 42 sodium (Na⁺) 42
ion channels calcium 361 potassium 68-70 sodium 46
ion pumps 65
ionic currents 65-70 ischemic heart disease 88

J Japan Pharmaceutical Manufacturers Association 7
Japanese Ministry of Health, Labour, and Welfare 7

K Kaiser Permanente 277
Kaplan-Meier analysis 245
Kefauver-Harris Drug Amendment 196
Korotkoff sounds 59

L labeling, drug 181, 223, 298, 337, 346, 362, 376
large simple trials 235
last participant last visit, clinical trial 308
lead compound 93
lead optimization 55, 93
left ventricular diastolic dimension 318
ejection fraction 318 endocardial fraction shortening 318
size and function 320 systolic dimension 318
levaclude methadone 286
cycle approach, drug development 2, 374, 378, 380
linker, between transmembrane segments 70, 102, 104-105
lipids, in cell membranes 43
hydrated phospholipid bilayer 105
Lipinski’s ‘rule of 5’ 98
log hazard ratio 246
log odds ratio 247
log relative risk 247
logarithmic scale 214
logarithms, use of 246
logistic regression models 219
long QT syndrome. See inherited long QT syndrome.
lopinavir 291
loss of function, hERG channel 82
lower limit reference range 200
two-sided confidence interval 147

M M-cells. See myocardial cells major irreversible morbidity, cardiac 318
mapping, genetic 32
margin of error 250
Marketing Authorisation Application 10
marketing withdrawal. See drug withdrawals, from market
mechanisms of action 53
Medicaid claims 277
medical devices, postmarketing surveillance of 389
Medical Dictionary for Drug Regulatory Affairs 206
Medical Research Council 260
Medicare 277
medication errors 20, 329
null hypothesis 170
numerator, use in ratios 12
nurses 329

O
observational studies. See nonexperimental studies
odds ratio 218, 247, 306
Office of Drug Safety 271, 299
Office of New Drugs 272
Office of Surveillance and Epidemiology 271
oncology, pharmacotherapy for 316-318
optimal responders, to drug 383
optimization, of drug molecule. See lead optimization
oral, drug administration route 98
osteoarthritis 294
overuse, of health care services 334

P
palpitations 293
pancreas 301
parallel design, use in TQT study 151, 181
participant-level (patient-level) data. See individual patient/participant data
patch clamp technique 120
patent life, drug 319
patient-centered care 341
patient interviews 276
Patient Safety, report by the Institute of Medicine 342-344
patient-years events per 309
of follow-up 321
PDUFA. See Prescription Drug User Fee Act
perfect storm scenario, occurrence of torsades de pointes 358
pericardial/pleural effusion 317, 318
period effects, parallel study design 151
peristaltic contractions, in tubular hearts 56
peroxisome proliferator-activated receptor-gamma (PPAR-γ) 302
Per-protocol analysis population 314
Peto fixed-effects model, in meta-analysis 313
pharmaceutical biotechnology, terminology 126
Pharmaceutical Research and Manufacturers of America (PhRMA) 7
pharmacists 329
pharmacodynamics 136

genetic influence 383
pharmacoepidemiology 263, 273, 378
pharmacogenetics 383f
pharmacogenomics 383f
pharmacokinetics 99, 113-114
pharmacokinetic/pharmacodynamic modeling 178, 362
pharmacology studies 114
pharmacophore 95
pharmacoproteomics 384
pharmacotherapeutic continuum 385
pharmacovigilance 262, 270
pharmacovigilance plan, in ICH Guidance E2E 278-279
phase 0 to 4, action potential 65
phases I-III nomenclature, clinical trials 4-5
phase IV nomenclature, clinical trial 232-233
phenylpropanolamine 294
phosphorylation 50
PhRMA's QT Statistics Expert
Working Group 143, 161
physical examinations 198
pioglitazone 302, 309, 314
plasma membrane 43
point estimate 147, 167, 251
polyclonal antibodies 127
polymorphic ventricular arrhythmia 75
polynucleotide chain/strand 27
pooled data analysis 245
pooling, adverse events 245
pore, ion channel 45, 46
portfolio, of drug candidates 381-382
positive control 152-153
postmarketing surveillance 6, 263f
active 271, 380-381
postmarketing study commitments 369
posttranslational modifications 37, 50
preapproval safety data 223-227, 364-365
precision coefficient 169, 251
precision medicine 53-54, 385-386
preclinical research. See nonclinical research
preemption 376
premarketing safety database. See preapproval safety database
prenylamine 286
Prescription Drug User Fee Act 362
concerns regarding conflict of interest 363
prescription-event monitoring 271
preventable adverse drug reactions, cost of 344
Preventing Medication Errors, report by the Institute of Medicine 344-346
primary pulmonary arterial hypertension 294
principal component analysis 84
proarrhythmic cardiac safety, definition 17
probabilities 211
propensity scores analysis 315
properties, drug molecule 97
proportions 206
prostaglandins 295
proteasome 85
proteins 39-40
protein trafficking 71
acquired deficiency 85-86, 361-362
proteome 37
proteomics 35
public health perspective, regulatory agency 390
public health trials 238
publication bias 243
pulmonary embolism 386
pulmonary valve 56
purines 27
Purkinje fibers 64, 65
assay 120
pyrimidines 27

Q
QT data 141
QTc data 121, 141-144
QTc data variation, reasons for 359
QT dispersion 83
QT interval 62-63
QT prolongation 62-63
QT/RR relationship. See hysteresis quantitative structure-activity relationships 103

R
radio telemetry 121
radionuclide ventriculography 317
randomization schedule, in TGN1412 study 135
randomized pharmaceutical clinical trial, first 260
rate-limiting step, lead
optimization 93
receptor, drug 47-48, 95
recombinant DNA technology 32, 126, 301
recombinant proteins, molecular weight 126
recombination 32
RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes) trial 303, 308
reduction, refinement, and replacement (3Rs), of animal studies 112
Reference Member State 11
reference ranges 188-189
refractory period 67
registries
for follow-up patient data 276
regulatory proteins 37
relative risk 210, 247, 306
vs. absolute risk 298, 306-307
renal dysfunction 315
repaglinide 302
replicates, TQT study 155-158
replication, DNA 30
repolarization, ventricular 67
repolarizing ionic currents 66
research pharmacology studies 114-115
responders analysis 261
rheumatoid arthritis 295
risk assessment 364
risk, communication of 298, 322-323
Risk Communication Advisory Committee 373
risk difference 208
risk evaluation and mitigation strategies 377
risk management 299, 363
risk minimization action plan 268, 267-368
ritonavir 291
RNA 34, 37, 39
RNA splicing 34
Roberts, Nobel Laureate in Medicine 34
robustness, in meta-analysis 242, 253
rofecoxib 273, 294, 296-300
rosiglitazone 300-314
Royal Pharmaceutical Society of Great Britain 349
RR interval 163
‘rule of threes’ 235
S
Saccharomyces cerevisiae 127
safety pharmacology 115
safety profile 4, 193, 381
safety signal 268
sample size, TQT study 175
sampling variation 152
saquinavir 291
science of safety 380
scorpion toxin. See BmK-1 selective cyclooxygenase-2 inhibitors 295
Sentinel Initiative 357, 379, 393
sequential testing strategy 172
serial gatekeeping strategy 172
serious adverse events 205, 365
shift analysis 200
short QT syndrome 184-186
signal, safety. See safety signal single nucleotide polymorphism 35 sinoatrial node 64 site-directed mutagenesis 46 sparfloxacin 286 spatial compression, within DNA 30 spontaneous case reports 274 spontaneous reporting 267, 319 statistical power
in analysis of adverse events 226
in TQT study 359
Statistics, operational definition 194
stem cells 125
stratified medicine 385
Streptococcus pneumoniae 153
Streptomyces lividans, ion channel 102
streptomycin 260
stroke volume 58
structural heart disease 358
structural molecular engineering 96
structure-activity relationships 93, 103
suboptimal responder, to drug 383
substrate 49
sudden cardiac death 91
sulfonyltaurose 50
sulphonylureas 302
summary statistic, in meta-analysis 246
supraoptimal responder, to drug 383
supratherapeutic dose, TQT study 154, 170
Supreme Court, United States 376
surgical injuries 332
surveillance studies 233
active 271
surveys, of exposure and/or event 276
survival rate 298
syncope 76
systematic reviews 240
systole 57
systolic blood pressure 58

T

T1/2. See half-life
T4 lymphocyte counts 235
T-wave morphology 84
terfenadine 286-288
molecular weight 126
terodiline 286, 287-288, 289
TGN1412 study 135
thalamus 61
thalidomide 16, 197, 285

The Future of Drug Safety, report by the Institute of Medicine 373-375
therapeutic confirmatory studies 5
therapeutic dose
safety pharmacology studies 115
TQT study 154, 170
therapeutic exploratory studies 5
therapeutic use studies 5, 237
thiazolidinediones 302, 309
Thorough QT/QTc Study 134, 144
negative 168
positive 168
threshold of regulatory concern, TQT study 149,
other studies 320-321
threshold voltage, depolarization 68
three-dimensional geometry 96
three-dimensionality
DNA 28
drugs 51
drug receptors 51-52
thromboembolism 317
thymine 27
time at risk, of event 220
time-to-event analysis 220, 245,
310, 366
Tmax 113, 163
To Err Is Human, report by the Institute of Medicine 332-339, 380
torsades de pointes 53, 74
torsadogenic liability 86, 117,
125, 290, 358
total peripheral resistance of the systemic vasculature 60
toxicity profile. See safety profile
toxicological studies 116
toxicophore 95
TPE 83
trafficking. See protein trafficking
tranexamic acid 315
transcription, genetics 33, 84
transcriptomics 35
transfusion errors 332
transient ischemic attacks 293
translation, genetics 33, 84
translational research 340
translocation, of ions 45, 65
transmembrane potential 64
transmission genetics 31
transmural dispersion of repolarization 83
treatment effect, in meta-analysis 246f
TRIAD 84
tricuspid valve 56
tuberculosis 260

U
unacceptable cardiovascular risk 293, 320-322
unanticipated problem, adverse event as 369-372
underuse, of health care services 334
upper bound, one-sided confidence interval 149
upper limit
reference range 200
two-sided confidence interval 147
urine samples 198
utility. See decision analysis

V
valdecoxib 295
valves. See heart valves
valvular heart disease 295, 318
venous thrombosis 386
ventricles 55
ventricular arrhythmias 74
ventricular repolarization. See repolarization, ventricular
verapamil 361
‘very extensive metaboliser phenotype’ 50
VIGOR (Vioxx Gastrointestinal Outcomes Research) study 296
vital signs 202
voltage-gated, ion channel 47
voltage-sensing transmembrane segment 47

W
warfarin 386
washout period, in cross-over trials 151
weight
assigned to individual studies in meta-analysis 249-250
trial participants. See body weight
white, drosophila gene name 32
World Health Organization 269
wrong-site surgeries 332

X
xenobiotics 45
x-ray crystallography 102